Pharmafile Logo

News and Press Releases

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025

Capsida Biotherapeutics
info@capsida.com
1300 Rancho Conejo Blvd. Thousand Oaks, CA 91320

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...

Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024

Relation
enquiry@relationrx.com
Regent’s Place 338 Euston Road London NW1 3BG

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...

Category: BioManufacturing
Posted: November 6, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference

Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...

Category: Clinical Trials, Logistics
Posted: May 8, 2024

The Pistoia Alliance
info@pistoiaalliance.org
401 Edgewater Pl, Wakefield, Massachusetts, US

Recipharm attains major sustainability milestones

Approval of ambitious Greenhouse Gas emission reduction targets by SBTi Commitment to renewable electricity sourcing to 100.0% by 2024 and to 42.1% GHG emission reduction (Scope 1 and 2) by...

Category: Manufacturing and Packing
Posted: March 26, 2024

Recipharm

ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors

13 March 2024 -- Stockholm, Sweden -- ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company,...

Category: Biotechnology
Posted: March 13, 2024

Recipharm

Recipharm, Medspray and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology

Partnership will help bring breakthroughs in the nasal delivery of fragile biologics and small molecules to market 23 January 2023 -- Stockholm, Sweden -- Recipharm, a leading contract development and...

Category: Drug Delivery
Posted: January 23, 2024

Recipharm

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oral presentation highlights new findings about the efficacy of XACDURO for the treatment of monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus infections Researchers share global surveillance data on the in vitro activity of XERAVA (eravacycline) for injection on...

Category: Pharmaceutical
Posted: October 12, 2023

Innoviva
info@istx.com
Boston BioHub 35 Gatehouse Drive Waltham, MA USA 02451